Evidence map›Paper›PMID 39682147›Full record

ReviewCancers2024

Machine Perfusion as a Strategy to Decrease Ischemia-Reperfusion Injury and Lower Cancer Recurrence Following Liver Transplantation.

Karla Bracho Garcia, Ahmed Hussein, Sangeeta Satish, Chase J Wehrle, Omer Karakaya, Rebecca Panconesi, Keyue Sun, Chunbao Jiao, Eduardo Fernandes, Antonio Pinna and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Karla Bracho GarciaDepartment of Liver Transplantation, Cleveland Clinic Weston Hospital, Weston, FL 33331, USA.ORCID 0000-0002-1015-8069
Ahmed HusseinDepartment of Liver Transplantation, Cleveland Clinic Weston Hospital, Weston, FL 33331, USA.ORCID 0009-0004-0450-3470
Sangeeta SatishTransplantation Center, Department of Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Chase J WehrleTransplantation Center, Department of Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH 44195, USA.ORCID 0000-0002-9275-4744
Omer KarakayaDepartment of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Rebecca PanconesiDepartment of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.ORCID 0000-0003-2708-1261
Keyue SunDepartment of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.ORCID 0000-0002-8928-4630
Chunbao JiaoDepartment of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.ORCID 0000-0002-9566-8243
Eduardo FernandesDepartment of Liver Transplantation, Cleveland Clinic Weston Hospital, Weston, FL 33331, USA.ORCID 0000-0003-1960-1001
Antonio PinnaDepartment of Liver Transplantation, Cleveland Clinic Weston Hospital, Weston, FL 33331, USA.ORCID 0000-0001-6523-3858
Koji HashimotoTransplantation Center, Department of Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Charles MillerTransplantation Center, Department of Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Federico AucejoTransplantation Center, Department of Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Andrea SchlegelTransplantation Center, Department of Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver transplantation (LT) is a key treatment for primary and secondary liver cancers, reducing tumor burden with concurrent improvement of liver function. While significant improvement in survival is noted with LT, cancer recurrence rates remain high. Mitochondrial dysfunction caused by ischemia-reperfusion injury (IRI) is known to drive tumor recurrence by creating a favorable microenvironment rich in pro-inflammatory and angiogenic factors. Therefore, strategies that decrease reperfusion injury and mitochondrial dysfunction may also decrease cancer recurrence following LT. Machine perfusion techniques are increasingly used in routine clinical practice of LT with improved post-transplant outcomes and increased use of marginal grafts. Normothermic (NMP) and hypothermic oxygenated machine perfusion (HOPE) provide oxygen to ischemic tissues, and impact IRI and potential cancer recurrence through different mechanisms. This article discussed the link between IRI-associated inflammation and tumor recurrence after LT. The current literature was screened for the role of machine perfusion as a strategy to mitigate the risk of cancer recurrence. Upfront NMP ("ischemia free organ transplantation") and end-ischemic HOPE were shown to reduce hepatocellular carcinoma recurrence in retrospective studies. Three prospective randomized controlled trials are ongoing in Europe to provide robust evidence on the impact of HOPE on cancer recurrence in LT.

Indexed as

disease-free survivalhepatocellular carcinomahypothermic oxygenated machine perfusion (HOPE)ischemia-reperfusion injuryliver transplantationmicroenvironmentmitochondrial injurynormothermic machine perfusiontumor recurrence

Identifiers

PMID39682147
PMCPMC11639801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.